logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
返回期刊详情
Cytotherapy 封面图

Cytotherapy

IF3.2
论文数8275
被引数6694
期刊论文 8275
发表时间
delete
Functional assessment reveals the properties of ABCG2-positive limbal stem cells derived from human pluripotent stem cells功能评估揭示了来源于人多能干细胞的ABCG2阳性角膜缘干细胞的特性
deleteCytotherapy
IF3.2
delete2026-10-28
delete0
PREAI
deleteTanja Ilmarinen; Gary Hin-Fai Yam; Meri Vattulainen; Jos Smits; Moira L Geary; Ella J Dewald; Taina Viheriälä; Huiqing Zhou; Vishal Jhanji; Heli Skottman
delete分享
delete收藏
Key Considerations for In Vitro Assessment of On- and Off-target/ Off-Disease Effects of Chimeric Antigen Receptor T-Cell Therapies嵌合抗原受体T细胞疗法在体内外评估其靶标和脱靶/脱病效应的关键考虑因素
deleteCytotherapy
IF3.2
delete2026-10-27
delete0
deleteOAAI
deleteShari A. Price; Alberto del Rio; George Papadapolous; Jonathan M. Clingan; Yi Yang; Louise Brackenbury; Sara Compte Sancerni; David Cobeta Lopez; Sabrina M. de Munnik; Louise Delsing; Rhiannon Shea; Jennifer Harbottle; Lucilia Pereira Mouriès; Robert Nunan; Parimal Pande; Lisa Scandiuzzi; ShinLa Shu; Sandy Eldridge; Connie L. Chen
delete分享
delete收藏
Optimization of a serum-free and stroma-free induction system for large-scale generation of functional red blood cells from human hematopoietic stem cells优化一种无血清和无基质诱导系统，用于从人造血干细胞大规模生成功能性红细胞
deleteCytotherapy
IF3.2
delete2026-10-24
delete0
PREAI
deleteZhe-Young Lin; Yun Chen; Cheng-Hao Wen; Chang-Hsun Tsai; Yu-Jen Chang; Yu-Tzu Tsao; Wei-Lun Huang; Chieh-Tsung Lo; Yi-Fang Tu; Po-Ming Wu; Chao-Ling Yao
delete分享
delete收藏
Practical Guide for Bench-to-Bedside Translation of Adoptive Cell Therapies: A Case-Based Series实用指南：基于案例系列的嵌合细胞疗法从实验室到临床的转化
deleteCytotherapy
IF3.2
delete2026-10-23
delete0
PREAI
deleteJasia Mahdi; Jay Tanna; Piriya Yoganathan; Christopher Chien; Michelle Monje; Steven Highfill; Patrick J. Hanley; Catherine M. Bollard; Fahmida Hoq; Naomi Taylor; Sneha Ramakrishna; Anant Vatsayan; Nirali N. Shah
delete分享
delete收藏
The Commercial Viability of Cell Therapy: We Cannot Continue to Accept the Status Quo细胞疗法的商业可行性：我们不能继续接受现状
deleteCytotherapy
IF3.2
delete2026-10-21
delete0
PREAI
deleteThomas R J Heathman; Keara Trinkle
delete分享
delete收藏
Cytokine-Independent Proliferation of CAR-T cells: Bug or Feature?细胞因子非依赖性CAR-T细胞增殖：缺陷还是特性？
deleteCytotherapy
IF3.2
delete2026-10-15
delete0
PREAI
deletePeirong Hu; Louisa Wirthlin; Alun Carter; Jonathan Dinsmore; Bernd Schoeder; Stefan Miltenyi; Juergen Schmitz; Mario Assenmacher; Boris Engels; Pradyot Dash; Rimas J. Orentas
delete分享
delete收藏
Clinical outcomes of CAR-T cell therapy in 21 patients with relapsed or refractory B-cell lymphoma involving the ileocecal region21例累及回盲部的复发或难治性B细胞淋巴瘤患者CAR-T细胞疗法的临床疗效
deleteCytotherapy
IF3.2
delete2026-10-15
delete0
deleteOAAI
deleteZeyan Shi; Xing Chen; Yue Chun; Fankai Meng; Yang Cao; Zhicheng Zhang; Zhenfang Liu; Wang Wei; Xiaojian Zhu
delete分享
delete收藏
A call to action: Position papers from the FDA Cell Therapy Liaison Meeting (CTLM) Working Group行动呼吁：FDA细胞疗法联络会议（CTLM）工作组立场文件
deleteCytotherapy
IF3.2
delete2026-10-15
delete0
PREAI
deleteOlive Sturtevant; Christina M. Celluzzi; Fajar Dumadi; Patrick Hanley
delete分享
delete收藏
Significant Differences in Infrastructure, Financing, and Workforce exist across Cell Therapy Manufacturing Facilities. A Report from BEST Collaborative.细胞疗法制造设施在基础设施、融资和劳动力方面存在显著差异。BEST合作组织报告。
deleteCytotherapy
IF3.2
delete2026-10-08
delete0
PREAI
deleteBeth Shaz; Deven Gupta; Anh Dinh; Joseph Schwartz; Suzanne Thibodeau; Magali Fontaine
delete分享
delete收藏
Clinical trials with Advanced Therapy Medicinal Products in Europe (2016–2025): the Regulators’ analysis欧洲先进治疗药物产品临床试验（2016–2025）：监管机构分析
deleteCytotherapy
IF3.2
delete2026-10-08
delete0
PREAI
deleteIlona G Reischl-Kok; Toine Egberts; Olga Kholmanskikh; Rozalina Kulaksazova; Denisa Marilena Margina; Dariusz Sladowski; Stefan Strasser; Giovanni Affronti; Francesca Scotti; Patrick Celis
delete分享
delete收藏
Safety, efficacy, and PK/PD of a BCMA-targeted CAR-NK cell therapy (LUCAR-B68) in relapsed/refractory multiple myeloma: a phase I studyBCMA靶向CAR-NK细胞疗法（LUCAR-B68）在复发/难治性多发性骨髓瘤中的安全性、有效性和PK/PD研究：一项I期研究
deleteCytotherapy
IF3.2
delete2026-10-02
delete0
PREAI
deleteShan Meng; Fangxia Wang; Ying Shen; Yang Zhang; Xuehong Ma; Aili He; Wanhong Zhao
delete分享
delete收藏
Sustainable Point-of-Care Manufacturing of Cell and Gene Therapies: Operational, Regulatory and Economic Pathways for Implementation可持续的细胞和基因疗法现场制造：实施的操作、监管和经济途径
deleteCytotherapy
IF3.2
delete2026-09-29
delete0
PREAI
deleteFolashade Otegbeye; Patrick J. Hanley; Emily L. Hopewell; Bambi J. Grilley; Olive Sturtevant; Joanne Kurtzberg; Rob Tressler
delete分享
delete收藏
What Drives Investment in Cell and Gene Therapy? Evidence from a Global Investor Survey of 100 Investors是什么驱动了细胞与基因疗法的投资？来自全球100位投资者的调查证据
deleteCytotherapy
IF3.2
delete2026-09-23
delete0
PREAI
deleteKsenia Bezverbnaya; Sandeep Mangrati; Asthika Goonewardene; Vered Gigi; Sven Kili; Patrick Rivers
delete分享
delete收藏
Interferon γ MSC accumulation in the lungs is mediated by integrin α4β1 adhesion干扰素γ介导的MSC在肺部的积聚是通过整合素α4β1黏附实现的
deleteCytotherapy
IF3.2
delete2026-09-20
delete0
PREAI
deleteElisabetta M. Foppiani; Andre J. Burnham; Edwin M. Horwitz
delete分享
delete收藏
Out of Specification frameworks may overestimate clinical risk: a lesson from commercial CAR-T products deviations超出规格框架可能高估临床风险：来自商业化CAR-T产品偏差的教训
deleteCytotherapy
IF3.2
delete2026-09-19
delete0
PREAI
deleteNatalia O. Ivanova; Anna I. Serdyuk; Ekaterina I. Fefelova; Arseniy E. Yuzhalin; Apollinariya V. Bogolyubova
delete分享
delete收藏
Pediatric autologous T-cell apheresis: does collection difficulty also predict manufacturing outcomes?儿科自体T细胞单采：采集难度是否也预测生产结果？
deleteCytotherapy
IF3.2
delete2026-09-17
delete0
PREAI
deleteWamiq Saeed; Zain ul Abideen Rao
delete分享
delete收藏
Characterization of Lentiviral Vector Products Using Orthogonal Measurements利用正交测量法表征慢病毒载体产品
deleteCytotherapy
IF3.2
delete2026-09-17
delete0
deleteOAAI
deleteJerilyn R. Izac; Zhiyong He; Linhua Tian; Edward Kwee; Sahana Audithan; Lili Wang
delete分享
delete收藏
Patient access to cell and gene therapies through the European hospital exemption pathway in the Netherlands通过欧洲医院豁免途径在荷兰实现患者对细胞和基因疗法的获取
deleteCytotherapy
IF3.2
delete2026-09-16
delete0
deleteOAAI
deleteChristine C. van Hattem; Lourens T. Bloem; Christianne M.A. Reijnders; Gwylim E.P.J. Janssens; Toine C.G. Egberts; Babs O. Fabriek
delete分享
delete收藏
Large-particle T-cell activation improves manufacturability, reduces phagocytic loss, and enhances CAR-T cell cytotoxic function大颗粒T细胞激活提高生产可行性，减少吞噬性损失，并增强CAR-T细胞细胞毒性功能
deleteCytotherapy
IF3.2
delete2026-09-09
delete0
deleteOAAI
deleteMatic Bartol; Tina Fink; Tina Tragin; Ema Pleško; Roman Jerala; Hana Esih; Aljaž Kravanja; Brina Štante; Valentina Bianco; Luka Fajs; Mojca Jež
delete分享
delete收藏
Calibrated prediction of CD34+ yield and apheresis product CD34+ concentration for allogeneic donor collection planning异基因供者采集计划中CD34+细胞产率和采集产物CD34+浓度的校准预测
deleteCytotherapy
IF3.2
delete2026-09-07
delete0
PREAI
deleteHilmi Erdem Gözden; Bedrettin Orhan; Nihan Alkış
delete分享
delete收藏